Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical propranolol gel for moderate to severe epistaxis in hereditary hemorrhagic telangiectasia
MOH_2017-11-14_001945Phase 2Not yet recruiting
- Sponsor
- דר' מאיר מי זהב
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hereditary hemorrhagic telangiectasia (HHT) comparing Propranolol then open-label propranolol with Placebo then open-label propranolol (2 arms). Planned start May 2017; status: not yet recruiting.
02
Drugs
propranolol
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on MOH_2017-11-14_001945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-14_001945.